Teeth problems associated with X-linked hypophosphatemia (XLH) are characterized by poor mineralization of several tooth tissues and jawbones, as well as defective mechanical properties, a study in mice suggests. The study, “Dentoalveolar Defects in the…
More than 80% of people with X-linked hypophosphatemia (XLH) develop hyperparathyroidism as a side effect of treatment with oral phosphate and active vitamin D, a study reports. Tertiary hyperparathyroidism, which results from prolonged hyperparathyroidism, is hard to treat. Surgical removal of the parathyroid glands is not…
Extended use of Crysvita (burosumab) for up to 48 weeks maintains normal blood levels of phosphate, relieves pain and stiffness, and aids the healing of bone fractures and overall physical condition of adults with X-linked hypophosphatemia (XLH), an extension study of a Phase 3 trial shows.
Get regular updates to your inbox.